Vir Biotechnology, Inc. VIR revenue by segment, product and geography
In its fiscal year ending 2025-12-31, Vir Biotechnology, Inc. reported revenue across 1 business segments; the largest, Reportable Segment, was $68.6M, 100.0% of the filed sum (-7.6% against the prior period in the same filing).
Reported segment mix
figures as filed · share of the filed sum · change vs the prior period in the same filing- Reportable Segment$68.6M100.0%-7.6% yoy
Members sum to the consolidated $68.6M for this period.
- Profit Sharing Amount-$1.14M50.0%-112.5% yoy
- License And Collaboration Revenue-$1.14M50.0%-113.6% yoy
- Profit Sharing Amount Constrained$00.0%-100.0% yoy
- Profit Sharing Amount Previously Constrained Released$00.0%no prior
Members sum to -$2.28M against $68.6M consolidated (residual $70.8M) - eliminations or corporate lines the filer did not tag on this axis.
- United States$2.04M100.0%-82.3% yoy
Members sum to $2.04M against $68.6M consolidated (residual $66.5M) - eliminations or corporate lines the filer did not tag on this axis.
- Reportable Segment-$29K100.0%-101.0% yoy
Change is against the same quarter a year earlier, as reported in the same 10-Q.
Source: SEC DERA Financial Statement and Notes data sets. Dimensional XBRL facts on the business-segment, product/service and geographic axes; the engine keeps the accession of every figure. Descriptive and educational, not advice.
About these figures
Companies tag segment, product and geographic revenue as dimensional XBRL facts in their 10-K and 10-Q filings. The SEC publishes those facts in its DERA Financial Statement and Notes data sets; TrendNalysis ingests each monthly file and serves the facts exactly as filed, keyed to the accession of the filing. Shares are of the filed sum. Where a filer tags more than one breakdown on one axis, the sum exceeds consolidated revenue and no shares are computed; where the members do not add up to the consolidated figure, the residual is stated rather than hidden. Missing is never zero.
Descriptive and educational; not investment advice. Methodology and data lineage.